Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GCLC | P48506 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22354643 | 0.82 | HSD17B10 (0.39) | HSD17B10SLC6A9APEX1KDM4EALDH1A1 | |
| SCHEMBL23904651 | 0.82 | HSD17B10 (0.41) | HSD17B10SLC6A9SMN1; SMN2APEX1S1PR1 | |
| SCHEMBL15496587 | 0.81 | HSD17B10 (0.44) | HSD17B10SLC6A9TP53SMN1; SMN2PIK3CD | |
| SCHEMBL26434198 | 0.78 | HSD17B10 (0.36) | HSD17B10SLC6A9APEX1S1PR1 | |
| SCHEMBL19016168 | 0.78 | HSD17B10 (0.36) | HSD17B10SLC6A9APEX1S1PR1 | |
| SCHEMBL22344786 | 0.77 | HSD17B10 (0.40) | HSD17B10SLC6A9SMN1; SMN2APEX1S1PR1 | |
| SCHEMBL22344784 | 0.77 | HSD17B10 (0.40) | HSD17B10SLC6A9SMN1; SMN2APEX1S1PR1 | |
| SCHEMBL22779191 | 0.76 | SMN1; SMN2 (0.40) | HSD17B10SMN1; SMN2KDM4EALDH1A1S1PR1 | |
| SCHEMBL10024737 | 0.74 | HSD17B10 (0.44) | HSD17B10SLC6A9TP53SMN1; SMN2TACR1 | |
| SCHEMBL8742080 | 0.71 | HSD17B10 (0.62) | HSD17B10SLC6A9SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046743-B2 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | ANTAROS MEDICAL AB (SE) | 2021-06-29 | — | — | US | disclosed |
| US-20200262885-A1 | SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES | ANTAROS MEDICAL AB (SE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262885-A1 | SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES | GLP1R, GCGR, GIPR | HSD17B10 4571/4885SLC6A9 914/4885TP53 3379/4885 |
| US-11046743-B2 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | GLP1R, GCGR, GIPR | HSD17B10 4571/4885SLC6A9 914/4885TP53 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.